The Use of tPA Alone for Fibrinolysis is based on a Misunderstanding that has Cost Many Lives

Main Article Content

Victor Gurewich, MD



Article Details

How to Cite
GUREWICH, Victor. The Use of tPA Alone for Fibrinolysis is based on a Misunderstanding that has Cost Many Lives. Medical Research Archives, [S.l.], v. 8, n. 10, oct. 2020. ISSN 2375-1924. Available at: <>. Date accessed: 25 june 2024. doi:
Research Articles


1. Boersma E, Maas ACP,Deckers JW et al Early thrombolytic treatment in acute myocardial infarction; reappraisal of the golden hour. Lancet 1996; 348:771-75.
2. Brophy JM, Joseph L. Placing trials in context using Bayesian analysis. GUSTO revisited by Reverend Bayes. JAMA 1995;273:871-75.
3. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007;357;1121-35.
4. Assessment of the safety and efficacy of a new treatment strategy with coronary intervention (ASSENT-4 PCI): a randomized trial. Lancet 2006; 367:569-78.
5. GUSTO Angiographic investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329:1615-22.
6. Husain SS, Gurewich V. Purification and partial characterization of a single-chain, high molecular weight form of urokinase from human urine. Arch Biochem Biophys 1983;220(1):31-38.
7. Park S, Harker LA, Marzec UM, Levin EG. Demonstration of single-chain urokinase plasminogen activator on human platelet membrane. Blood 1989; 73:1421-25.
8. Gurewich V, Johnstone M, Loza JP, Pannell R. Pro-urokinase and prelkallikrein are both associated with platelets: implications for the intrinsic pathway of fibrinolysis. Thromb Haemost 1994;71:347-52.
9. Jiang YP, Pannell R, Liu JN, Gurewich V. Evidence of a novel biding protein for urokinase plasminogen activator in platelet membranes. Blood 1996; 87:2775-81.
10. Lenich C, Liu JN, Gurewich V Thrombin stimulation of platelets induces plasminogen activation mediated by endogenous urokinase-type plasminogen activator. Blood 1997; 90:3579-86.
11. Pannell R, Black J, Gurewich V. The complementary modes of action of tissue plasminogen activator (tPA) and pro-urokinase (pro-UK) by which their synergistic effect in clot lysis can be explained. J Clin Invest 1988;
12. Husain SS, Lipinsli B, Gurewich V. Rapid purification of high affinity plasminogen activator from human plasma on fibrin-celite. Proc Nat Acad Sci (USA). 1981; 78(7):4265-69.
13. Hoylaerts M, Rijken DC, Lijnen JR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem. 1982; 257:2912-19.
14. Liu JN, Gurewich V. Fragment E-2 from fibrin substantially enhances pro-urokinase induced glu-plasminogen activation. A kinetic study using a plasmin-resistant mutant (Ala-158 rpro-urokinase). Biochemistry 1992; 31:6311-17.
15. Petersen LC. Kinetics of reciprocal pro-urokinase/plasminogen activation. Stimulation by a template formed by the urokinase receptor bound to poly (D-lysine). Euro J Biochem 1997; 245:316-23
16. Singh I, Burnand KG, Collens M, Luttun A, Collen D, Boelhouwer B, Smith A. Failure of a thrombus to resolve in urokinase-type gene knockout mice. Circulation 2003;107;869-75.
17. Zarich SW, Kowalchuk GJ, Weaver WD, Loscalzo J. Sassower M, Manzo K,Byrnes C, Muller JE Gurewich V. Sequential combination thrombolytic therapy for acute myocardial infarction: results of the pro-urokinase and tPA enhancement of thrombolysis (PATENT) trial. J AM Coll Cardio 1995; 26:374-79.
18. GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Eng J Med 1993;329:673-82.